M Carrie Miceli

Title(s)Professor, MIMG
SchoolMedicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke University Medical Center , Durham, North CarolinaPhD1988Immunology
    Stanford University Medical Center, Palo Alto, CAPostdoc1993Immunology
    UCSD, La Jolla, CABA1983Biochemistry and Cell Biology

    Collapse Research 
    Collapse Research Activities and Funding
    Muscle Cell Biology, Pathophysiology, and Therapeutics
    NIH T32AR065972May 1, 2016 - Apr 30, 2026
    Role: Co-Principal Investigator
    Identification of Enhancers of Therapeutic Exon Skipping for DMD
    NIH RC1AR058333Sep 25, 2009 - Aug 31, 2011
    Role: Principal Investigator
    Galectin-1 regulation of T cell activation and tolerance
    NIH R01AI056155Jun 15, 2003 - Nov 30, 2008
    Role: Principal Investigator
    Coreceptor Modification of TCR Tyrosine Kinase Signals
    NIH R01AI067253Dec 8, 1994 - Mar 31, 2011
    Role: Principal Investigator
    CORECEPTOR MODIFICATION OF TCR TYROSINE KINASE SIGNALS
    NIH R01CA065979Dec 8, 1994 - Jun 30, 2005
    Role: Principal Investigator
    CORECEPTOR MODIFICATION OF TCR TYROSINE KINASE SIGNALS
    NIH R29CA065979Dec 8, 1994 - Jun 30, 2000
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Single nuclei transcriptomics of muscle reveals intra-muscular cell dynamics linked to dystrophin loss and rescue. Communications Biology. 2022; 989(5). Scripture-Adams DD, Chesmore, K.N., Barthélémy, F Wang RT, Nieves-Rodriguez S, Wang DW, Mokhonova EI, Douine ED, Wan J, Little I, Rabichow LN, * Nelson SF, and * Miceli MC *denotes equal contributions.
    2. Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels. Front Cell Dev Biol. 2022; (10). Barthélémy F*, Santoso JW*, Rabichow L, Jin R, Little I, Nelson SF, McCain ML*, Miceli MC* .
    3. Immuno-mass spectrometry imaging of skeletal muscle dystrophin. Scientific Reports. 2021; (11). Bishop et al.
    4. A Well Tolerated Core Needle Biopsy Process for Children and Adults. Muscle and Nerve. 2020; 6(62):688-698. Barthélémy, F, Woods, Nieves -Rodriguez, Wang, R, Wanagat, *Miceli, MC, *Nelson, S.F. 62(6):688-698, 2020. *joint senior authors.
    5. Targeting RyR activity boosts antisense exon 44 and 45 skipping in human DMD skeletal or cardiac muscle culture models. Molecular Therapy, Nucleic Acids. 2019; (18):580-589. Barthélémy, F, Wang, RT, Hsu, C, Douine, ED. Nelson, SF and Miceli, M.C.
    6. Large in-frame 5’deletions in DMD associated with mild Duchenne Muscular Dystrophy: two case reports and a review of the literature. 2019; (29):863. Gibbs, EM, Barthélémy, F. Douine ED , Hardiman, N, Shieh, PB, Khanlou, N, Crosbie-Watson, RHC*, Nelson, SF* and Miceli, MC*.. *denotes equal contribution.
    7. DMD Genotype Correlations from the Duchenne Registry: endogenous exon skipping, is a factor in prolonged ambulation for individuals with a defined mutation sub-type. Human Mutation. 2018; (39):1193. Wang, RT*, Barthelemy, F*. Martin, ED, Douine, D, Eskin, A. Lucas, Lavigne, JA. L Peay, H., Khanlou, N, Cantor, RM. Cantor, Miceli. M.C.*, Nelson SF* equal contributions.
    8. Repurposing Dantrolene for Long-term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx mouse. Molecular Therapy: Nucleic Acids. 2018; June 11. Wang, DW, Mokhonova, EI, Kendall, GC, Becerra, D., Naeini, Y, Spencer, MJ, Cantor, R. Nelson, SF*, Miceli, MC* . (2018 Vol. June 11: 180-191 *. Miceli and Nelson share senior authorship. .
    9. The case for eteplirsen: Paving the way for precision medicine. Mol Genet Metab. 2016 06; 118(2):70-1. Miceli MC, Nelson SF. PMID: 27102846.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    10. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell. 2016; 4(18):533-40. Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA, Kohn DB, Nakano A, Nelson SF, Miceli MC, Spencer MJ, Pyle AD. Apr 7;18(4):533-40 PMID: 26877224; PMCID: PMC4826286 (Journal cover).
    11. Osteopontin Ablation Ameliorates Muscular Dystrophy by shifting macrophages to a pro-regenerative phenotype. Journal of Cell Biology. 2016; (25):275. Capote J, Kramerova I, Martinez L, Vetrone S, Barton ER, Sweeney HL, Miceli MC, Spencer, MJ.
    12. Discs Large Homolog 1 splice variants regulate p38 dependent and Independent Effector Functions in CD8+ T cells. PLOS One. 2015. Silva, O, Crocetti, J, Humphries, J, Burkhardt, J and M. C. Miceli (2015). .
    13. Selective phosphorylation of the Dlg1AB variant is critical for TCR-induced p38 activation and induction of proinflammatory cytokines in CD8+ T cells. Journal of Immunology. 2014; 6(193):2651-60. Crocetti J*, Silva O*, Humphries LA, Tibbs MD, Miceli MC. *denotes equal contributions.
    14. Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy. Science Translational Medicine. 2012; 164(4):164. Kendall GC*, Mokhonova E*, Moran M, Sejbuk NE, Wang DW, Silva O, Wang RT, Martinez Lu, Damoiseaux R, Spencer MJ *, Nelson SF*, † Miceli MC*, †. equal contributions..
    15. Characterization of in vivo Dlg1 deletion on T cell development and function. PLoS ONE. 2012; 9(7). Humphries, L.A., Shaffer, M.H., Sacirbegovic, F., Tomassian, T., McMahon, K.-A., Humbert, P.O., Silva, O., Round, J.L., Takamiya, K., Huganir, R.L., Burkhardt, J.K., Russell, S.M., Miceli, M.C.
    16. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus. 2011; 5(20):473. Liu S.D., Lee, S., La Cava, A., Motran, C.C., Hahn*, B.H., Miceli*, M.C.
    17. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus. 2011; 5(20):473. Liu S.D., Lee, S., La Cava, A., Motran, C.C., Hahn*, B.H., Miceli*, M.C.
    18. Caveolin-1 orchestrates synaptic polarity, signal specificity and function in CD8 T cells. J Immunology. 2011; (187):2993-3002. Tomassian, T, Humphries, L., Lui, S.D., Silva, O. Brooks, D., Miceli, M.C.
    19. Osteopontin promotes fibrosis in Mdx muscle through modulation of immune cell subsets and intramuscular TGFbeta. Journal of Clinical Investigation, 119 (6):1583-1594, 2009. 2009; 6(119). Vetrone, S.A., Montecino-Rodriguez, E., Kudryashova, E., Kramerova, I., Hoffman, E.P., Liu, S.D., Miceli, M.C., Spencer M.J.
    20. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. Journal of Immunology. 2009; 9(182):5283-5395. 27. Liu, S.D., Tomassian, T., Miceli, M.C., 182 (9):5283-5295, 2009.
    21. Endogenous galectin-1 functions to enforce class I restricted TCR functional fate decisions in thymocytes. Blood. 2008; 1(112):120. Liu, S.D, Chung, C.D, Tomassian, T, Pang, M, Baum, L.G, Miceli, M.C. E. , 112 (1):120-130, 2008.
    22. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. European Journal of Immunology. 2008; 11(38):3015. Motran, C. Molinder K.M., Liu S.D., Poirer, F., Miceli, M.C. .
    23. Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-kB transcription factors. Nature Immunology. 2007; 154(8). Round, JL, Humphries, LA, Tomassian, T, Mittelstadt, P, Zhang M, Miceli, M.C. , 8:154, 2007.
    24. Dlgh1 coordinates actin polymerization, synaptic TCR and lipid raft aggregation and effector function in T lymphocytes. 23. Round, J.L., Tomassian, T., Zhang, M., Patel, P., Schoenberger, S.P., Miceli, M.C. Journal of Experimental Medicine . 2005; (3):419-430. Round, J.L., Tomassian, T., Zhang, M., Patel, P., Schoenberger, S.P., Miceli, M.C. .
    25. CD45 signals outside of lipid rafts to promote synaptic raft clustering, Erk activation and IL-2 production. Journal of Immunology. 2005; 3(174):1479. Zhang, M., Moran, M., Round, J., Low, T., Patel, V., Tomassian, T., Hernandez, J.D., Miceli M.C. .
    26. Co-stimulation and counter-stimulation: lipid raft clustering controls TCR signaling and functional outcomes. Semin Immunol. 2001 Apr; 13(2):115-28. Miceli MC, Moran M, Chung CD, Patel VP, Low T, Zinnanti W. PMID: 11308295.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    27. A molecular framework for two step T cell signaling: Lck SH3 domain mutations discriminate two distinctly regulated lipid raft reorganization events. Journal of Immunology. 2001; (166):754. Patel, V., Moran, M., Low, T., Miceli, M.C.
    28. Caveolin-1 orchestrates synaptic polarity, signal specificity and function in CD8 T cells. J Immunol. Journal of Immunology. 2001; (187):2993-3002. Tomassian, T, Humphries, L., Lui, S.D., Silva, O. Brooks, D., Miceli, M.C.
    29. Galectin-1 induces partial beta chain phosphorylation and antagonizes processive TCR signal transduction. Journal of Immunology. 2000; (165):3722. Chung, C.D., Patel, V.P., Moran, M., Lewis L.A., Miceli, M.C.
    30. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis, but inhibit proliferation and IL-2 production. Journal of Immunology. 1999; (162):799. Vespa, G.N.R, Kozak, K., Lewis, L., Moran, M., Ngyen J.T., Baum, L.G., Miceli, M.C.
    31. TCR-Induced IL-2 production and apoptosis have different requirements for Lck activities. Journal of Immunology. 1999; (162):799-806. Vespa, G.N.R, Kozak, K., Lewis, L., Moran, M., Ngyen J.T., Baum, L.G., Miceli, M.C. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis, but inhibit proliferation and IL-2 production.
    32. Engagement of GPI-anchored T cell CD48 contributes to TCR signals and cytoskeletal reorganization: A role for lipid rafts in T cell activation. Immunity, 9:787-796, 1998. 1998; (9):787-796. Moran, M., Miceli MC.
    33. The Lck SH2 phosphotyrosine binding site is critical for efficient TCR-induced processive tyrosine phosphorylation of the beta chain and IL-2 production. Journal of Immunology. 1997; (159):2292. Lewis, L.A., Chung, C.D., Chen, J., Parnes, J.R., Moran, M.M., Patel, V.P., Miceli, M.C.
    34. TCR-Induced IL-2 production and apoptosis have different requirements for Lck activities. Journal of Immunology. 1997; (159):1758-66. Chung, C.D., Lewis, L.A., Miceli, M.C. , 159:1758-1766, 1997.
    35. Adhesion versus coreceptor functions of CD4 and CD8: Role of the cytoplasmic tail in coreceptor activity. Proceedings of the National Academy of Sciences,. 1991; (88):2623. Miceli, M.C., von Hoegen, P., Parnes, J.R. USA, 88:2623-2627, 1991.
    36. Enhancement of T cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Nature. 1991; (350):62-66. Abraham, N., Miceli, M.C., Parnes, J.R., Veillette, A. .
    37. T cell receptor beta chain selection in human allograft rejection. J Immunol, 142:81-88, 1989. Journal of Immunoly, 142:81-88, 1989. 1989; (142):81-88. Miceli, MC, Finn, OJ.
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    M's Networks
    Concepts (31)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California